02575 軒竹生物－Ｂ
XUANZHUBIO-B
XUANZHUBIO-B
| Listing Date | 2025/10/15 |
| Listing Price | 11.600 |
Subscription Result
- Subscription Rate4,908.33x
- Guarantee One Lot Size--
- One Lot Success Rate1%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Xuanzhu Biopharmaceutical Co is a biopharmaceutical company in China.
--
As of September 26, 2025, the Group had over ten drug assets under active development covering digestive diseases, oncology and non-alcoholic steatohepatitis (NASH), including three NDA approved assets, one drug program in NDA registration-stage, one drug program in phase 3 clinical trial, four drug programs in phase 1 clinical trial and five at IND-approved stage.
--
The Group have three Core Products, namely, KBP-3571, an NDA-approved innovative proton pump inhibitor (PPI) for digestive diseases, XZP-3287, an NDA-approved cyclin-dependent kinase 4/6 (CDK4/6) inhibitor targeting breast cancer (BC), and XZP-3621, an NDA-approved anaplastic lymphoma kinase (ALK) inhibitor targeting non-small cell lung cancer (NSCLC), of which KBP-3571 and XZP-3287 have been commercialized. It owned 15 issued patents in China and 28 issued patents in the U.S. and other jurisdictions
--
The Group’s customers were mainly distributors. As of September 26, 2025, the Group had over 105 distributors, covering a network of over 1,700 hospitals nationwide in China.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 67.33M H shares |
| No. of International Offer Shares | 60.60M H shares |
| No. of HK Offer Shares | 6.73M H shares |
| Offer Price | $11.60 |
| Stock Code | 2575 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, CMB International Capital Limited |
TIME TABLE
| Application Period | Oct 06 (Mon) - noon, Oct 10 (Fri) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Oct 14 (Tue) |
| Result Announcement Date | On or before Oct 14 (Tue) |
| Result Announcement Date | On or before Oct 15 (Wed) |
| Dealings in Shares commence on | Oct 15, 2025. (Wed) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $11.60 |
| Capitalization (H Shares) | 1.86B |
| NAV / share ($) | $1.86 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 11.6, the net proceeds raised would be HKD 701.00M, of which |
| 45% : Research, development and commercialization of Core Products |
| 14% : Research and development of key products |
| 11% : Research and development of other drug candidates |
| 20% : Strengthening commercialization and marketing capabilities |
| 10% : Working capital |
IPO NEWS
| 15/10/2025 16:08 |
| {New Stock}XUANZHUBIO-B(02575) ends up 126.72% at HK$26.3 |
| 14/10/2025 18:35 |
| {New Stock}XUANZHUBIO-B ends up 171.21% on grey market |
| 14/10/2025 16:20 |
| {New Stock}XUANZHUBIO-B(02575) up 134.66% on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).